HIV Drug Resistance and the Advent of Integrase Inhibitors

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2012 Nov 27

PMID 23180144

Citations 18

Authors

Peter K Quashie

Thibault Mesplede

Mark A Wainberg

Affiliations

Soon will be listed here.

Abstract

This review focuses on the topic of HIV integrase inhibitors that are potent antiretroviral drugs that efficiently decrease viral load in patients. However, emergence of resistance mutations against this new class of drugs represents a threat to their long-term efficacy. Here, we provide new information about the most recent mutations identified and other mutations that confer resistance to several integrase inhibitors, such as new resistance mutations-for example, G118R, R263K, and S153Y-that have been identified through in vitro selection studies with second-generation integrase strand transfer inhibitors (INSTIs). These add to the three main resistance pathways involving mutations at positions Y143, N155, and Q148. Deep sequencing, structural modeling, and biochemical analyses are methods that currently help in the understanding of the mechanisms of resistance conferred by these mutations. Although the new resistance mutations appear to confer only low levels of cross-resistance to second-generation drugs, the Q148 pathway with numerous secondary mutations has the potential to significantly decrease susceptibility to all drugs of the INSTI family of compounds.

Citing Articles

Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.

Tatsing Foka F, Tumelo Mufhandu H Viruses. 2023; 15(8).

PMID: 37632074 PMC: 10458198. DOI: 10.3390/v15081732.

HIV and Drug-Resistant Subtypes.

Nastri B, Pagliano P, Zannella C, Folliero V, Masullo A, Rinaldi L Microorganisms. 2023; 11(1).

PMID: 36677513 PMC: 9861097. DOI: 10.3390/microorganisms11010221.

Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.

Richetta C, Subra F, Malet I, Leh H, Charpentier C, Corona A J Virol. 2022; 96(14):e0067622.

PMID: 35758669 PMC: 9327692. DOI: 10.1128/jvi.00676-22.

First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients.

Ghasabi F, Hashempour A, Khodadad N, Bemani S, Keshani P, Shekiba M Biochem Biophys Rep. 2022; 30:101254.

PMID: 35368742 PMC: 8968007. DOI: 10.1016/j.bbrep.2022.101254.

Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.

Rombini F, Cecchini D, Ballivian J, Huberman M, Uruena A, Cassetti I Rev Esp Quimioter. 2020; 34(1):56-60.

PMID: 33267555 PMC: 7876904. DOI: 10.37201/req/090.2020.

References

Schafer J, Squires K . Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother. 2009; 44(1):145-56. DOI: 10.1345/aph.1M309. View

Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M . The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother. 2011; 66(12):2827-30. DOI: 10.1093/jac/dkr389. View

Eron Jr J, Rockstroh J, Reynes J, Andrade-Villanueva J, Ramalho-Madruga J, Bekker L . Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011; 11(12):907-15. DOI: 10.1016/S1473-3099(11)70196-7. View

McNeely M, Hendrix J, Busschots K, Boons E, Deleersnijder A, Gerard M . In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75. J Mol Biol. 2011; 410(5):811-30. DOI: 10.1016/j.jmb.2011.03.073. View

Wills T, Vega V . Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012; 21(3):395-401. DOI: 10.1517/13543784.2012.658914. View

Canducci F, Sampaolo M, Marinozzi M, Boeri E, Spagnuolo V, Galli A . Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009; 23(4):455-60. DOI: 10.1097/QAD.0b013e328323da60. View

Engelman A, Cherepanov P . The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012; 10(4):279-90. PMC: 3588166. DOI: 10.1038/nrmicro2747. View

Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

Al-Mawsawi L, Al-Safi R, Neamati N . Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008; 13(2):213-25. DOI: 10.1517/14728214.13.2.213. View

10.

Song I, Borland J, Min S, Lou Y, Chen S, Patel P . Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011; 55(7):3517-21. PMC: 3122457. DOI: 10.1128/AAC.00073-11. View

11.

Zolopa A, Berger D, Lampiris H, Zhong L, Chuck S, Enejosa J . Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010; 201(6):814-22. DOI: 10.1086/650698. View

12.

Jayappa K, Ao Z, Yang M, Wang J, Yao X . Identification of critical motifs within HIV-1 integrase required for importin α3 interaction and viral cDNA nuclear import. J Mol Biol. 2011; 410(5):847-62. DOI: 10.1016/j.jmb.2011.04.011. View

13.

Eron J, Young B, Cooper D, Youle M, DeJesus E, Andrade-Villanueva J . Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010; 375(9712):396-407. DOI: 10.1016/S0140-6736(09)62041-9. View

14.

Oliveira M, Brenner B, Wainberg M . Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol. 2008; 485:427-33. DOI: 10.1007/978-1-59745-170-3_29. View

15.

Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T . Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2009; 54(1):254-8. PMC: 2798521. DOI: 10.1128/AAC.00842-09. View

16.

Li X, Krishnan L, Cherepanov P, Engelman A . Structural biology of retroviral DNA integration. Virology. 2011; 411(2):194-205. PMC: 3640404. DOI: 10.1016/j.virol.2010.12.008. View

17.

Krishnan L, Li X, Naraharisetty H, Hare S, Cherepanov P, Engelman A . Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A. 2010; 107(36):15910-5. PMC: 2936642. DOI: 10.1073/pnas.1002346107. View

18.

Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P . Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009; 63(4):795-804. DOI: 10.1093/jac/dkp014. View

19.

. Single-tablet Quad regimen achieves high rate of virologic suppression. AIDS Patient Care STDS. 2010; 24(3):197. DOI: 10.1089/apc.2010.9909. View

20.

Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L . Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011; 66(7):1481-3. DOI: 10.1093/jac/dkr152. View